Drug-related Infectious Diseases (DRID) key indicator annual expert meeting, 15-16 June 2015, Lisbon
Belgium
Bulgaria
EMCDDA meeting on the key indicator on Drug-related Infectious Diseases (DRID)
15-16 June 2015 - Lisbon
This year, the DRID key epidemiological indicator meeting focused on the following topics: updating the regional assessment of HIV risk and response; hepatitis C infections and treatment; botulism and other infections; emerging risks related to the injection of stimulants, including new psychoactive substances; and drug-related health issues among prison populations. The meeting kicked off with a summary of the most recent trends and updates by the national experts, based on 2015 ‘national abstracts’ followed by two sets of parallel technical workshops and four ‘conference-like’ plenaries. Attendance at the expert meeting was restricted to nominated experts from the 28 EU Member States, Norway and Turkey and invited speakers. Our European partners – namely the European Commission and WHO Europe – as well as experts from non-EU countries have contributed to this year’s meeting.
The event took place at the EMCDDA’s Conference Centre in Lisbon, Portugal, starting on the morning of Monday, 15 June 2015 and ending on Tuesday, 16 June lunchtime (see agenda on the right). A call for input to the DRID meeting was sent to the expert networks and the deadline for submission of proposals for input and abstracts was 1 June 2015 (see templates on the side).
Key documents:
Supporting documents
- Mission report: HIV and hepatitis B and C in Latvia
- Wound botulism in people who inject heroin in Norway and the United Kingdom - ECDC/EMCDDA, Lisbon, February 2015
- Contaminated heroin warning - Wound Botulism - Public Health England
- Wound Botulism: Outbreak Questionnaire - Public Health England
- Anthrax Outbreak Information PWID Germany
- Contaminated Heroin - Botulism - Postcard Scotland
- Public Health England - Health & Justice report 2014
Presentations
Plenary session 1 - Aims and objectives, summary of latest data from national abstracts, rapid updates
- Presentation of the objectives and expectations - Isabelle Giraudon, EMCDDA
- Most recent data, analyses and feedback from the 2015 ‘national abstracts’ - Eleni Kalamara EMCDDA
- Rapid updates: Experimentation of drug consumption rooms in France - Anne-Claire Brisacier, France
- Rapid updates: Increase in injecting cocaine use and a parallel increase of HIV infections - Alain Origer, Luxembourg
- International updates: European Commission: new EU Joint Action on HIV - Matthias Schuppe, DG Santé
- International updates: WHO global health sector strategies - Antons Mozalevskis, WHO Europe
Parallel session A. TDI data: consistencies and inconsistencies with DRID data
- Behavioural data in the TDI and DRID data collection in Greece - Anastiasios Fotiou, Greece
- Information on infectious diseases in/from registers on treatment and services for DUs in the Czech Republic - Barbara Janikova, Czech Republic
- Behavioral Data in TDI and DRID Data Collection in Croatia - Marko Markus, Croatia
- TDI and DRID behavioural data: preliminary assessment of consistency of HIV and HCV testing data - Linda Montanari, EMCDDA
Parallel session B. Detecting and responding to new threats: NPS injection and other risks
- The impact of and responses to injecting NPS in South Wales - Josephine Smith, Wales, UK
- Impact of increasing NPS injecting combined with weakening responses: infections and risk behaviours - Anna Tarján, Hungary
- Rapid updates: Acetylfentanyl-deaths/harm reported in the UK - Michael Evans-Brown, EMCDDA
- New HIV cases possibly related to mephedrone injection? - Margaret Curtin, Ireland
Parallel session C. HIV risk assessment updates
- HIV risk assessment updates: introduction - Dagmar Hedrich, EMCDDA
- HA-REACT Joint Action on HIV and coinfection prevention and harm reduction - Henrikki Brummer-Korvenkontio, Finland
- Prevalence of HIV and risk behaviours among PWID: an update, using data from cross-sectional study among PWID, conducted in Narva, 2014 - Maris Salekešin, Estonia
- Update on DRID among PWID: focus on recent institutional response - Lavinius Sava, Romania
- Update on risk of drug-related infections among PWID: results from a new prevalence study among PWID - Evelina Venckevic, Lithuania
- Harm reduction: who is responsible? The case of the syringe exchange programme in Israel - Daniel Chemtob, Israel
Parallel session D. Outbreaks: botulism and others
- Update on the cluster of wound botulism and discussion around diagnosis availability - Hans Blystad/Astrid Lovlie, Norway
- An outbreak of botulism associated with people who use drugs in Scotland - Gillian Penrice, United Kingdom
- Information/prevention targeted at drug users and professionals (Rapid updates and discussion) - Vivian Hope, United Kingdom
- Rapid update: Injection in risky body parts and injection abscesses: epidemiology - Karin de Ridder, Belgium
- Rapid update: Not in the vein: ‘missed hits’, subcutaneous and intramuscular injections among people who inject psychoactive drugs in Bristol - Vivian Hope, United Kingdom
- Rapid update on the situation in Germany - Ruth Zimmermann, Germany
Plenary session 2 - The health of prisoners: a focus on infectious diseases
- Drugs and Prison in Europe: a focus on infectious diseases - Linda Montanari, EMCDDA
- The health of prisoners: a focus on infectious diseases - Eamonn O’Moore, WHO Collaborating Centre
- Drug prevalence in prisons of Latvia in 2014 - Irina Lucenko, Latvia
- Infectious diseases in Spanish prisons - Elena Alvarez, Spain
- Prevalence of drug-use and BBV among the Irish prison population - Margaret Curtin, Ireland
- Health without barriers - Roberto Monarca, European Federation for Prison Health
- Monitoring harm reduction implementation in European prisons: public health and human rights approaches - Cinzia Brentari, Harm Reduction International
Plenary session 3 - Scaling up responses to hepatitis C infection in Europe: what is next needed?
- Hepatitis C in the WHO European Region - Antons Mozalevskis, WHO Europe
- HCV treatment and prevention: what is the impact of current treatment rates in selected sites in Europe? - Hannah Woodall, United Kingdom
- ‘Break Through’ project on hepatitis C in addiction care: a care path from screening to treatment and aftercare for HCV-positive drug users - Esther Croes, Netherlands
- Rapid updates: Prices of the new generation of HCV medicines: survey among national focal points - Claudia Costa Storti, EMCDDA
- Rapid updates: Regulation of expenses for hepatitis C treatment in France - Anne-Claire Brisacier, France
- Factors associated with undiagnosed hepatitis C infection among PWID: missed opportunities for diagnostic testing - Vivian Hope, United Kingdom
- Joint Procurement of medical countermeasures - European Commission
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>
Contact
The EMCDDA is located at:
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
